CPX-351: a nanoscale liposomal co-formulation of daunorubicin and cytarabine with unique biodistribution and tumor cell uptake properties

od Mayer, Lawrence D, Tardi, Paul, Louie, Arthur C
Izdano u Int J Nanomedicine (2019)

Persistent Cytarabine and Daunorubicin Exposure after administration of Novel Liposomal Formulation CPX-351: Population Pharmacokinetic Assessment

od Nikanjam, Mina, Capparelli, Edmund V., Lancet, Jeffrey E., Louie, Arthur, Schiller, Gary
Izdano u Cancer Chemother Pharmacol (2017)

First-In-Man Study of CPX-351: A Liposomal Carrier Containing Cytarabine and Daunorubicin in a Fixed 5:1 Molar Ratio for the Treatment of Relapsed and Refractory Acute Myeloid Leuk...

od Feldman, Eric J., Lancet, Jeffrey E., Kolitz, Jonathan E., Ritchie, Ellen K., Roboz, Gail J., List, Alan F., Allen, Steven L., Asatiani, Ekatherine, Mayer, Lawrence D., Swenson, Christine, Louie, Arthur C.
Izdano u J Clin Oncol (2011)

Phase II, Multicenter, Randomized Trial of CPX-351 (cytarabine:daunorubicin) Liposome Injection versus Intensive Salvage Therapy in Adults with First Relapse AML

od Cortes, Jorge E., Goldberg, Stuart L., Feldman, Eric J., Rizzeri, David A., Hogge, Donna E., Larson, Melissa, Pigneux, Arnaud, Recher, Christian, Schiller, Gary, Warzocha, Krzysztof, Kantarjian, Hagop, Louie, Arthur C., Kolitz, Jonathan E.
Izdano u Cancer (2014)

A phase 2 study to assess the pharmacokinetics and pharmacodynamics of CPX-351 and its effects on cardiac repolarization in patients with acute leukemias

od Lin, Tara L., Newell, Laura F., Stuart, Robert K., Michaelis, Laura C., Rubenstein, Eric, Pentikis, Helen S., Callahan, Timothy, Alvarez, Donna, Liboiron, Barry D., Mayer, Lawrence D., Wang, Qi, Banerjee, Kamalika, Louie, Arthur C.
Izdano u Cancer Chemother Pharmacol (2019)

Unsatisfactory efficacy in randomized study of reduced-dose CPX-351 for medically less fit adults with newly diagnosed acute myeloid leukemia or other high-grade myeloid neoplasm

od Walter, Roland B., Othus, Megan, Orlowski, Kaysey F., McDaniel, Emily N., Scott, Bart L., Becker, Pamela S., Percival, Mary-Elizabeth M., Hendrie, Paul C., Medeiros, Bruno C., Chiarella, Michael T., Louie, Arthur C., Estey, Elihu H.
Izdano u Haematologica (2018)

Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML

od Lancet, Jeffrey E., Cortes, Jorge E., Hogge, Donna E., Tallman, Martin S., Kovacsovics, Tibor J., Damon, Lloyd E., Komrokji, Rami, Solomon, Scott R., Kolitz, Jonathan E., Cooper, Maureen, Yeager, Andrew M., Louie, Arthur C., Feldman, Eric J.
Izdano u Blood (2014)

CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemi...

od Lancet, Jeffrey E., Uy, Geoffrey L., Cortes, Jorge E., Newell, Laura F., Lin, Tara L., Ritchie, Ellen K., Stuart, Robert K., Strickland, Stephen A., Hogge, Donna, Solomon, Scott R., Stone, Richard M., Bixby, Dale L., Kolitz, Jonathan E., Schiller, Gary J., Wieduwilt, Matthew J., Ryan, Daniel H., Hoering, Antje, Banerjee, Kamalika, Chiarella, Michael, Louie, Arthur C., Medeiros, Bruno C.
Izdano u J Clin Oncol (2018)